Skip to main content
Premium Trial:

Request an Annual Quote

Richard Eglen, Timothy Mullane, Bernelle Saperstien, Amnis, Amaxa

Premium

Migrations

Richard Eglen has left DiscoverX to become vice president and general manager of discovery and research reagents for PerkinElmer's Life and Analytical Sciences unit, where he will be responsible for developing and executing PerkinElmer's discovery and research reagents business strategy.

Eglen previously held the post of chief scientific officer and executive vice president for research and development at DiscoverX. Prior to his employment at DiscoverX, Eglen served as senior vice president of assays and reagents for LJL Biosystems. He also has held various positions at Roche, including vice president and director of the Center for Biological Research at Roche Bioscience. Eglen earned his PhD in molecular pharmacology from Trent University in the UK.

CBA News has also learned that Timothy Mullane has joined DiscoverX as president.

Mullane most recently was employed by Hayward, Calif.-based Biolog, where he served as president and CEO. According to the DiscoverX website, Mullane has also held various positions in operations, business development, and sales and marketing management for Boehringer Mannheim, Biotrack, Ciba Corning, Baxter, and American Hospital Supply. Mullane has a BA in microbiology.


ForteBio announced this week that Bernelle Saperstien has joined the company in the newly created position of vice president, manufacturing operations.

Saperstein joins ForteBio from Becton Dickinson Immunocytometry Systems, where she led a team responsible for manufacturing and testing reagents for cell analysis. Prior to this, Saperstein was vice president of operations at First Medical, a subsidiary of Sigma Diagnostics. She also has held positions Roche Diagnostics and Merck. Saperstein holds a BS in chemical engineering from Virginia Tech.

 

Products

Amnis this week announced the release of the "Turbo" upgrade for its flagship ImageStream flow-based imaging system.

According to Amnis, the upgrade provides a three- to five-fold increase in data collection speed, a more than two-fold increase in sensitivity, and extensive engineering changes that have improved the system's reliability. Amnis also said that it made a number of modifications to the IDEAS and INSPIRE software packages used to operate the platform.

The Turbo upgrade is now standard on all ImageStream systems, and the company is providing the upgrade at no charge to existing customers "in recognition of their early support for the technology." Amnis expects to have every system upgraded by the end of this year, it said.


Amaxa this week launched its Nucleofector 96-well Shuttle system for DNA or siRNA transfection into cells. The new product is a high-throughput version of the Nucleofector platform, which was able to perform one transfection at a time in single cuvettes. The company said that DNA and siRNA can be delivered using the same protocol, and that libraries may be pre-plated and stored in disposable Nucleocuvette modules, which can then be used in the 96-well array.

Last month, Amaxa said that it had signed a deal with Fisher Biosciences unit Dharmacon to co-promote the Nucleofector 96-well Shuttle system with Dharmacon's siRNA reagents (see CBA News, 6/9/2006).

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.